Spotlight
Video

Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

cancergrace has 795 videos Subscribe Here

Loading........
Description: http://cancerGRACE.org/...

Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.

GRACEcastUC 137 Lung
Shared By : cancergrace
Posted on : 06/24/13
Added : 4 years ago
Category : Brain Cancer